PMID- 32356477
OWN - NLM
STAT- MEDLINE
DCOM- 20210121
LR  - 20220415
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 19
IP  - 6
DP  - 2020 Jun
TI  - Nothing is perfect: the safety issues of integrase inhibitor regimens.
PG  - 683-694
LID - 10.1080/14740338.2020.1764531 [doi]
AB  - INTRODUCTION: Since the administration of the first integrase strand transfer 
      inhibitor (INSTI) in 2007, most international treatment guidelines consider 
      INSTI-based regimens to be the preferred antiretroviral combinations for 
      HIV-1-infected patients as a result of their safety and efficacy profile. INSTIs 
      are generally well tolerated, and reported rates of discontinuation due to 
      drug-related adverse events (AEs) have been very low to date. However, recent 
      reports indicate that physicians should be aware of potential INSTI-related AEs 
      to ensure good clinical practice. AREAS COVERED: The authors performed a critical 
      review of the safety issues affecting INSTIs based on published evidence from 
      original studies and new data from researchers. EXPERT OPINION: Almost all 
      antiretroviral drugs, including INSTIs, are associated with undesirable AEs. 
      Dolutegravir in particular has been associated with more frequent AEs such as 
      neuropsychiatric disorders, neural tube defect in newborns, and weight gain. Data 
      with bictegravir in routine practice are still scarce. While this association and 
      its clinical relevance are not clear, physicians should be alert to the 
      appearance of the aforementioned AEs and others in the future. In the meantime, 
      INSTIs continue to be the preferred option in guidelines on antiretroviral 
      therapy.
FAU - Scevola, Sofia
AU  - Scevola S
AD  - HIV and STI Unit, Infectious Disease Service, Hospital Universitari de 
      Bellvitge-IDIBELL, Universitat de Barcelona, L'Hospitalet de Llobregat , 
      Barcelona, Spain.
FAU - Tiraboschi, Juan Manuel
AU  - Tiraboschi JM
AD  - HIV and STI Unit, Infectious Disease Service, Hospital Universitari de 
      Bellvitge-IDIBELL, Universitat de Barcelona, L'Hospitalet de Llobregat , 
      Barcelona, Spain.
FAU - Podzamczer, Daniel
AU  - Podzamczer D
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200522
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Amides)
RN  - 0 (HIV Integrase Inhibitors)
RN  - 0 (Heterocyclic Compounds, 3-Ring)
RN  - 0 (Heterocyclic Compounds, 4 or More Rings)
RN  - 0 (Oxazines)
RN  - 0 (Piperazines)
RN  - 0 (Pyridones)
RN  - 8GB79LOJ07 (bictegravir)
RN  - DKO1W9H7M1 (dolutegravir)
SB  - IM
MH  - Amides
MH  - Animals
MH  - Drug Therapy, Combination
MH  - HIV Infections/*drug therapy/virology
MH  - HIV Integrase Inhibitors/administration & dosage/*adverse effects
MH  - HIV-1/isolation & purification
MH  - Heterocyclic Compounds, 3-Ring/administration & dosage/adverse effects
MH  - Heterocyclic Compounds, 4 or More Rings/administration & dosage/adverse effects
MH  - Humans
MH  - Oxazines/administration & dosage/adverse effects
MH  - Piperazines/administration & dosage/adverse effects
MH  - Pyridones/administration & dosage/adverse effects
OTO - NOTNLM
OT  - Adverse events
OT  - HIV
OT  - antiretroviral therapy
OT  - integrase strand transfer inhibitors
OT  - safety
EDAT- 2020/05/02 06:00
MHDA- 2021/01/22 06:00
CRDT- 2020/05/02 06:00
PHST- 2020/05/02 06:00 [pubmed]
PHST- 2021/01/22 06:00 [medline]
PHST- 2020/05/02 06:00 [entrez]
AID - 10.1080/14740338.2020.1764531 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2020 Jun;19(6):683-694. doi: 10.1080/14740338.2020.1764531. 
      Epub 2020 May 22.